Marinomed Biotech AG announces grant of Chinese Patent covering the proprietary Marinosolv technology to generate aqueous solutions from insoluble compounds
July 15, 2021
Corporate News

Korneuburg, Austria, July 15, 2021 – Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, is pleased to announce that the Chinese State Intellectual Property Office (SIPO) has granted the patent covering the Marinosolv platform and its solubilizer properties. Specifically, the patent protects Marinosolv as a method for generating aqueous solutions of therapeutically or cosmetically relevant organic compounds that are insoluble or only slightly soluble in water. The Marinosolv platform enables the solubilization of many hardly soluble compounds, which opens new possibilities for precisely treating a multitude of diseases.

“The Marinosolv patent in China is an important international reinforcement of the technology platform and supports our continued efforts in further establishing and advancing Marinosolv-based products. We consider both the Marinosolv-based products and the underlying technology central cornerstones for the company’s future development,” said Dr. Andreas Grassauer, Chief Executive Officer of Marinomed. “The Chinese market offers huge potential for the treatment of allergic diseases. This patent will help Marinomed to benefit from these opportunities.”

“The data from Marinosolv formulated product candidates so far have demonstrated significant efficacy given the comparatively low dosage: this is true for Tacrosolv, a soluble Tacrolimus formulation in development to treat hay fever, as well as for our two corticosteroid formulations against allergic rhinitis, Budesolv and Flutisolv. The increased solubility enables a significantly faster onset of action, better bioavailability and more efficient delivery, making treatment more convenient for patients,” said Dr. Eva Prieschl-Grassauer, Chief Scientific Officer at Marinomed. “We are confident that formulations based on the Marinosolv technology generally offer much quicker improvement of symptoms for patients suffering from allergic rhinitis, allergic conjunctivitis and a broad range of further conditions where faster relief leads to a significantly improved quality of life.”

Full Press Release (Download)